Chemotherapy resistance in acute leukemia

Turkish Journal of Haematology

Volumn 17, Issue 4, 2000, Pages 155-162

  Chauncey, T R ^a  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

Acute Leukemia; MRP1; Pgp; Resistance

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; PROTEIN BCL 2; VALSPODAR;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL TRIAL; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SPECIFICITY; DRUG TRANSPORT; HUMAN; HYPERBILIRUBINEMIA; PREDICTION; PROTEIN EXPRESSION; REVIEW; TREATMENT OUTCOME; TUMOR RESISTANCE;

EID: 0034526634     PISSN: 13007777     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Multidrug resistance in haematological malignancies
2. The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia
3. In vitro effect of multidrug resistance modifiers on idarubicinol efflux in blasts of acute myeloid leukemia
4. Effect of PSC 833 on the cytotoxicity of idarubicin and idarubicinol in multidrug-resistant K562 cells
5. An inventory of the human ABC proteins
6. Molecular aspects of hepatobiliary transport
7. Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines
8. A multidrug resistance transporter from human MCF-7 breast cancer cells
9. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia
10. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia
11. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study
12. P-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance-associated protein (MRP) expression in acute promyelocytic leukaemia
13. Influence of SDZ-PSC833 on daunorubicin intracellular accumulation in bone marrow specimens from patients with acute myeloid leukemia
14. Novel mechanisms of drug resistance in leukemia
15. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia
16. Functional MDR1 expression in adult acute lymphoblastic leukemia (ALL)
17. Expression of the multidrug resistance P glycoprotein in newly diagnosed adult acute lymphoblastic leukemia: Absence of correlation with response to treatment
18. The expression of the multidrug resistance related glycoprotein in adult acute lymphoblastic leukemia
19. Lung resistance-related protein: Determining its role in multidrug resistance
20. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia
21. Vaults are up-regulated in multidrug-resistant cancer cell lines
22. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia
23. Drug resistance factors in acute myeloid leukemia: A comparative analysis
24. Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia
25. Lung resistance protein (LRP) gene expression in adult acute myeloid leukemia: A critical evaluation by three techniques
26. Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome
27. Evidence for a critical role of DNA topoisomerase II alpha in drug sensitivity revealed by inducible antisense RNA in a human leukaemia cell line
28. Topoisomerase II activities in AML blasts and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines
29. Resistance to the chemosensitizer verapamil in a multi-drug-resistant (MDR) human multiple myeloma cell line
30. Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance
31. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833
32. Topoisomerase II levels and DNA fragmentation in leukemia blasts treated with topotecan followed by etoposide + mitoxantrone (T-EM) in a timed sequential chemotherapy regimen
33. Topoisomerase II and the response to antileukemic therapy
34. Characterization of newly established human myeloid leukemia cell line (KF-19) and its drug resistant sublines
35. Leukaemia cell drug resistance and prognostic factors in AML
36. Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia
37. Bcl-2, bax and bcl-xL expression in human sensitive and resistant cell lines
38. Measurement of spontaneous and therapeutic agent-induced apoptosis with BCL-2 protein expression in acute myeloid leukemia
39. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia
40. Benefit of cyclosporine (CsA) modulation of anthracycline resistance in high-risk AML: A Southwest Oncology Group (SWOG) study
41. A randomized phase III study of cyclosporine (CSA) modulation of anthracycline resistance in CML-blast phase: Southwest Oncology Group (SWOG) Study 9032
42. Comparison of two chemotherapy regimens, with or without cyclosporine A, in relapsed/refractory acute myeloid leukaemia: Results of the U.K. Medical Research Council AML-R Trial
43. Mitoxantrone, etoposide and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: An Eastern Cooperative Oncology Group pilot study
44. Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia
45. P-glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia
46. A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: A Southwest Oncology Group Study (9617)
47. Parallel phase I studies of daunomycin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myelogenous leukemia: Results of Cancer and Leukemia Group B Study 9420
48. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC833 (valspodar)
49. Phase III study of PSC-833 modulation of multidrug resistance (MDR) in previously untreated acute myeloid leukemia (AML) patients (PTS) > 60 years (CALGB 9720)
50. Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs MEC: Randomized phase III trial (E2995)
51. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979
52. Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias
53. P-glycoprotein and multidrug resistance-associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myeloid leukaemic cells
54. Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia
55. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin
56. Parallel phase I trials of multi-drug resistance (MDR) modulation with PSC-833 (PSC) in untreated patients with acute myeloid leukemia (AML) < 60 years old: Preliminary results of CALGB 9621